A new study funded by the National Institutes of Health (NIH) has found that a symptom-based approach to treating newborns experiencing opioid withdrawal can help infants recover faster and leave the hospital sooner.
The research focused on neonatal opioid withdrawal syndrome (NOWS), a condition that occurs when babies exposed to opioids during pregnancy experience withdrawal symptoms after birth. NOWS has become increasingly common amid the ongoing opioid epidemic and can cause feeding difficulties, excessive crying, tremors, sleep disturbances, and other health complications.
Traditionally, infants with moderate to severe NOWS are treated using scheduled doses of opioid medications that are gradually tapered over time. However, researchers found that administering opioid medications only when withdrawal symptoms reached a predetermined threshold reduced overall medication exposure and shortened recovery times.
The findings come from the Optimizing Pharmacologic Treatment for Neonatal Opioid Withdrawal Syndrome (OPTimize NOW) clinical trial, which enrolled 383 infants receiving care through the family-centered Eat, Sleep, Console (ESC) approach. The ESC model focuses on helping babies eat effectively, sleep adequately, and be comforted by caregivers before relying on medication.
Of the infants studied, 194 received traditional scheduled opioid treatment, while 189 received symptom-based dosing only when withdrawal symptoms reached a specified level. Safeguards were built into the study to ensure infants whose symptoms did not improve received additional treatment when needed.
Researchers found that infants treated with symptom-based dosing were ready for discharge approximately two days earlier than those receiving scheduled treatment. The symptom-based group also stopped opioid medications sooner.
“Scheduled opioid dosing, which includes a taper, is necessary for some infants with NOWS, however it may overtreat others,” said lead author Dr. Lori Devlin, a professor of pediatrics at the University of Louisville and Norton Children’s Neonatology. “The idea is that by matching treatment to disease severity, we can accelerate recovery and minimize exposure.”
The benefits were not observed among infants initially cared for using the older, provider-centered Finnegan assessment method rather than the ESC approach.
Researchers say the findings could influence treatment practices nationwide. Several hospitals that participated in the trial have already adopted the symptom-based strategy.
“The opioid epidemic is still a huge problem, but this is a simple and powerful way we can get these babies ready to go home faster,” said Dr. Augusto Schmidt of NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development. “This is best for their family and for their own development.”
The study was supported through the NIH HEAL Initiative, which focuses on developing scientific solutions to address opioid misuse, addiction, and pain management. Results were published in the Journal of the American Medical Association under the title Symptom-Based Dosing for Neonatal Opioid Withdrawal: Outcomes from the OPTimize NOW Study.
About the Author
Discover more from Right Now Oregon
Subscribe to get the latest posts sent to your email.
